Enovis CORP price to free cash flow ENOV

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: 19.1×
10-year median: 16.8×
Against its 10-year history: 53rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 10.5× to 409×
Peer median: 17.6×

Enovis CORP's price to free cash flow is 19.1× as of Oct 23, 2026.

That is above its ten-year median of 16.8×, close to the middle of its last ten years.

Over that time it ranged from 10.5× in Feb 2018 to 409× in Feb 2020.

The median for 10 medical instruments and supplies stocks of a similar size is 17.6×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	19.1×	16.0×	75.6×
2025	68.8×	66.5×	76.0×
2024	236×	236×	269×
2023	n/m a value too high to mean anything
2022	58.1×	12.8×	69.4×
2021	14.5×	13.9×	21.0×
2020	19.7×	13.5×	409×
2019	39.9×	11.2×	39.9×
2018	11.7×	10.5×	35.1×
2017	12.9×	11.1×	16.7×
2016	14.5×	7.1×	15.8×

Against its peers

Companies in Medical - Instruments & Supplies nearest Enovis CORP's size, closest first, today.

Company	Price to free cash flow
ENOVEnovis CORP	19.1×
BVSBioventus	13.3×
CDRECadre	16.4×
STAAStaar Surgical	n/m
IRMDIradimed	43.7×
EYENational Vision	30.1×
LMATLemaitre Vascular	26.2×
INSPInspire Medical Systems	17.6×
MOVMovado	9.8×
UFPTUFP Technologies	n/m
MDXGMimedx	n/m
Peer median	17.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Enovis CORP

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.